销售价格: | ¥ N/A |
商品编号: | AI-0124-0366 |
软件语言: | 英文 |
器械分类: | II |
生产厂家: | Combinostics |
公司网址: | https://www.combinostics.com/ |
认证信息: | FDA |
系统要求: | Windows |
交付方式: | 下载安装 |
cNeuro® cDSI
Our AI-driven software tools support early detection, differential diagnosis, prediction of progression, and patient monitoring in memory disorders.
cNeuro® cDSI, our cloud-based software, supports the clinician in the challenging work of analyzing the large amount of data required for confident decisions around patient care. By combining key patient data from multiple sources, cDSI provides clinical decision support for early, differential diagnosis; prediction of disease progression; and decisions about what testing is needed in patients with neurodegenerative diseases.
Access and review key patient data in one location
Review and assess relevant patient data, including demographic and clinical data, neuropsychology test results, imaging findings, and biomarkers, all presented in a compact, intuitive view.
Demographics
Age
Gender
Clinical and neuropsychological tests
MMSE
MoCA
RAVLT/CERAD recall and delayed recall
TMT A&B
Animal fluency
NPI
Other biomarkers
CSF
APOE
Validated cMRI imaging biomarkers
Volumes on brain structures
Lesion load
Disease-specific biomarkers
Diagnose earlier and with greater confidence
cDSI integrates multiple sources of patient data and compares the findings to a large database of previously diagnosed cases, providing a quantitative estimate (the disease state index) of the patient’s similarity with different disease groups. This not only improves the consistency of neurological interpretations but also provides information about which disease is the most likely diagnosis using intuitive, interactive visualizations.
Use decision models for diagnosis
Decision models are available for Alzheimer’s disease (AD), frontotemporal dementia (FTD), vascular dementia (VaD), and cognitively normal (CN).
redict disease progression
Access support for the prediction of disease progression and long-term outcomes
Support testing decisions
Identify patients for whom additional, expensive testing (e.g., lumbar puncture, amyloid PET) would be beneficial.
A study showed that our computer-supported prediction reduces CSF testing to only 26% of cases, without compromising diagnostic accuracy.
cDSI-Related Publications
非常抱歉,您只有购买软件后才能查看完整软件教程!